A benzothiazole-carbazole hybrid derivative, its preparation method and application
By designing benzothiazole-carbazole hybrid compounds, the problem of single-target therapy in existing Alzheimer's drugs has been solved, achieving synergistic effects of multi-target therapy, effectively inhibiting Aβ aggregation and protecting nerve cells.
Patent Information
- Application Number
- CN202311105517.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-30
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2043-08-30
AI Technical Summary
Current Alzheimer's disease drug treatments mostly target a single point, making it difficult to effectively stop the disease from worsening. Furthermore, the existing benzothiazole derivatives have relatively simple pharmacological effects and cannot comprehensively improve symptoms.
We designed benzothiazole-carbazole hybrid compounds to develop multi-target drugs that exhibit antioxidant effects, copper ion chelation, inhibition of Aβ aggregation, and inhibition of cholinesterase activity.
It achieves multi-target therapy for Alzheimer's disease, with synergistic effects, effectively inhibiting Aβ aggregation, protecting nerve cells, and improving cognitive function.
Smart Images

Figure CN119119020B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of benzothiazole-carbazole hybrid compounds, and more particularly to a benzothiazole-carbazole hybrid derivative, its preparation method, and its application. Background Technology
[0002] Alzheimer's disease (AD) is a common type of dementia characterized by progressive, irreversible memory loss, cognitive and language impairments, and is one of the most common and serious chronic diseases among the elderly. Since current drugs can only slow disease progression and cannot fundamentally improve symptoms, research into drugs targeting AD is urgently needed. However, the complex pathogenesis of AD is a major obstacle to drug development. It is currently believed that the development of AD is related to multiple pathological mechanisms, including amyloid deposition, tau protein phosphorylation, oxidative stress, acetylcholine deficiency, and metal ion imbalances. Research evidence suggests that single-target drug therapy is insufficient to halt the progression of the disease or improve AD. Therefore, developing multi-target drugs is considered an effective approach to treating this disease.
[0003] Benzothiazole heterocycles serve as a multifunctional scaffold in medicinal chemistry, possessing a wide range of biological activities. Studies have found that unsubstituted 2-benzothiazole compounds and their derivatives can effectively inhibit Aβ aggregation and reduce the content of soluble amyloid oligomers in vivo and in vitro. Chinese Patent Application No. 201110434465.4 discloses a benzothiazole derivative and its uses, exhibiting inhibitory and imaging effects on β-amyloid protein aggregation and deposition. When used as an imaging agent, it requires labeling with a suitable radioisotope or a contrast agent suitable for magnetic resonance imaging. This compound can be used in the preparation of drugs for the prevention and treatment of diseases including Alzheimer's disease. However, this benzothiazole derivative only inhibits Aβ aggregation, exhibiting a relatively singular pharmacological effect. This invention aims to provide a novel compound with multiple pharmacological activities, such as antioxidant damage, copper ion chelation, inhibition of Aβ aggregation, and inhibition of cholinesterase activity, thereby enabling its use in the treatment of Alzheimer's disease. Summary of the Invention
[0004] To address the shortcomings of existing technologies, this invention designs benzothiazole-carbazole hybrids and their derivatives. These compounds can be used to prepare drugs for treating Alzheimer's disease through multi-target and synergistic effects. Another objective of this invention is to provide a method for preparing this series of derivatives.
[0005] To solve the above-mentioned technical problems, the technical solution of the present invention is as follows: a benzothiazole-carbazole hybrid compound and its derivatives, wherein the general formula of the compound is:
[0006]
[0007] Where X is a benzene ring or -NC-C6H6 or -N=C-C6H6; R1 is OH or -O-CH3;
[0008] R2 is
[0009] Preferably, the compound is selected from one or more of 4a, 4b, 4c, 5a, 5b, 5c, 6a, 6b, 6c, 7a, 7b, 7c, 8a, and 9a;
[0010] 4a: 4b:
[0011] 4c: 5a:
[0012] 5b: 5c:
[0013] 6a: 6b:
[0014] 6c: 7a:
[0015] 7b: 7c:
[0016] 8a: 9a:
[0017] Preferably, the compound contains one or more isotopically enriched atoms, specifically by replacing hydrogen with deuterium or tritium, or by using... 13 C or 14 C-enriched carbon atoms replace carbon atoms, or with 15 N-enriched nitrogen replaces nitrogen atoms.
[0018] In a second aspect, the present invention provides the use of the benzothiazole-carbazole hybrid compound and its derivatives in the preparation of anti-AD drugs.
[0019] Preferably, the compound possesses antioxidant damage-preventing effects, copper ion chelation effects, and inhibition of Aβ aggregation.
[0020] Inhibits cholinesterase activity.
[0021] In a third aspect, the present invention also provides a method for preparing the benzothiazole-carbazole heterocombinant compound, wherein the preparation methods of compounds 4a, 4b and 4c are as follows:
[0022] Compound 2, 2-amino-5-methoxybenzylthiophenol, and compound 3a-c Dissolve in DMSO, heat to react, and after the reaction is complete, cool the mixture to room temperature. Pour 3-5 times (volume) of ice water into the reaction solvent, extract three times with dichloromethane, wash the dichloromethane solution with water, and dry on anhydrous Na2SO4. Filter, evaporate the solvent under vacuum, and perform chromatographic analysis on a silica gel column with a mixture of n-hexane / CH2Cl2 in a ratio of 2.5-5:1 v / v as the eluent to obtain 4a, 4b, and 4c, respectively.
[0023] The molar ratio of compound 2 to compound 3a-c is 2-5:1; the ratio of compound 3a-c to DMSO is 1.5-2.0 mmol: 15-25 mL; the reaction temperature is 160-180℃, and the reaction time is 10-15 h.
[0024] The preparation methods of compounds 5a, 5b and 5c are as follows:
[0025] Slowly add 0.3-0.8 mmol of compound 4a-c to argon gas at -80℃ to -75℃. 25-35 ml of CH2Cl2 solution and 3-5 ml of anhydrous CH2Cl2 solution containing 3-5 mmol BBr3 were prepared; the mixture was gradually heated to room temperature and stirred for 18-25 h; after neutralization with saturated NaHCO3 solution, it was extracted three times with CH2Cl2; the resulting dichloromethane solution was washed with water and dried on anhydrous sodium sulfate, filtered, and the solvent was evaporated under vacuum. The crude product was eluent with CH2Cl2 and subjected to silica gel column chromatography to obtain white powders 5a, 5b and 5c.
[0026] In compounds 3a-c and 4a-c, R represents one of the structures:
[0027] Preferably, the preparation methods of compounds 6a, 6b and 6c are as follows:
[0028] Compound 1, 6-methoxybenzothiazole-2-amine, and compound 3a-c The mixture of acetic acid and ethanol was refluxed in ethanol for 5-8 hours, and then purified by recrystallization in ethoxyethanol and dichloromethane to give compounds 6a, 6b and 6c.
[0029] The molar ratio of compound 1 to compound 3a-c is 1.5-2.5:1; the ratio of compound 3a-c, glacial acetic acid, and ethanol is 1.5-2.0 mmol: 8-15 mL: 15-25 mL;
[0030] The preparation methods of compounds 7a, 7b and 7c are as follows:
[0031] Slowly add compound 6a-c into argon gas at 75℃~85℃ The THF solution and LiAlH4 were stirred for 15-25 h, and extracted three times with CH2Cl2. The resulting dichloromethane solution was washed with water and dried on anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was purified by recrystallization with diethyl ether and dichloromethane to obtain white powders 7a, 7b and 7c.
[0032] The ratio of the compound 6a-c, LiAlH4 and THF is 0.8-1.5 mmol: 3-4 mmol: 15-25 mL.
[0033] As a preferred embodiment, the preparation method of compound 8a is as follows: 25-35 ml of CH2Cl2 solution containing 0.8-1.2 mmol of 7a and 3-5 ml of anhydrous CH2Cl2 solution containing 3-5 mmol of BBr3 are slowly added to argon gas at -80℃ to -75℃. The mixture is gradually heated to room temperature and stirred for 15-25 h. After neutralization with saturated NaHCO3 solution, it is extracted three times with CH2Cl2. The resulting dichloromethane solution is washed with water and dried on anhydrous sodium sulfate. After filtration, the solvent is evaporated under vacuum. The crude product is eluent with CH2Cl2 and subjected to silica gel column chromatography to obtain compound 8a.
[0034] As a preferred embodiment, the preparation method of compound 9a is as follows: 25-35 ml of CH2Cl2 solution containing 0.4-0.7 mmol 6a and 3-5 ml of anhydrous CH2Cl2 solution containing 3-5 mmol BBr3 are slowly added to argon gas at -80℃ to -75℃. The mixture is gradually heated to room temperature and stirred for 15-25 h. After neutralization with saturated NaHCO3 solution, it is extracted three times with CH2Cl2. The resulting dichloromethane solution is washed with water and dried on anhydrous sodium sulfate. After filtration, the solvent is evaporated under vacuum. The crude product is eluent with CH2Cl2 and subjected to silica gel column chromatography to obtain compound 9a.
[0035] The compounds provided by this invention have novel structures and possess antioxidant and protective effects against oxidative damage, anti-amyloid aggregation (inhibition of Aβ aggregation), and inhibition of cholinesterase activity. Furthermore, compounds 5a and 8a exhibit copper ion chelation activity, which is advantageous for treating Alzheimer's disease, as excessive copper ions are considered one of the causes of Alzheimer's. Therefore, the compounds provided in this application can be used to prepare drugs for treating Alzheimer's disease through multi-target, synergistic effects.
[0036] Compared with the prior art, the beneficial effects of the present invention are as follows: The present invention links benzothiazole and carbazole through different group chains, the preparation method is simple to operate and has a high yield, and the prepared benzothiazole-carbazole hybrid compound is a small molecule drug with multi-target anti-AD effects, including anti-oxidative damage effect, copper ion chelation effect, inhibition of Aβ aggregation effect, inhibition of cholinesterase activity, etc., and can be used to prepare anti-AD drugs. Attached Figure Description
[0037] Figure 1 This invention provides a synthetic route for a benzothiazole-carbazole hybrid derivative.
[0038] Figure 2 This is a bar chart showing the cytotoxic effect of the present invention on HT22 cells;
[0039] Figure 3 The bar chart shows the protective effect of this invention against L-glutamate-induced HT22 cytotoxicity.
[0040] Figure 4 This is the UV-Vis absorption spectrum of the interaction between compounds 5a and 8a of the present invention and copper ions. Detailed Implementation
[0041] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. The reagents 1-bromo-1,2,2-triphenylethylene, 4-formylphenylboronic acid, tetrabutylammonium bromide (TBAB), tetra(triphenylphosphine)palladium [Pd(PPh3)4], potassium hydroxide (KOH), and boron tribromide (BBr3) used in the following embodiments were purchased from Alfaesa Reagents. Ultra-high pressure water (18 MΩcm) was used in the experiments. All other reagents and solvents were purchased from Guangzhou Dongzheng Company (China) of analytical grade and were not further purified.
[0042] This invention provides a benzothiazole-carbazole heterocomplex derivative, and the compound of general formula I is prepared as follows:
[0043]
[0044] Where X is a benzene ring or -NC-C6H6 or -N=C-C6H6; R1 is OH or -O-CH3;
[0045] R2 is
[0046] Its synthetic route is as follows Figure 1 As shown, the preparation process of each compound is described in the following examples.
[0047] The compounds of formula (I) of this invention also include pharmaceutically acceptable derivatives thereof, such as any pharmaceutically acceptable salt, prodrug, or salt of a prodrug of the compounds of this invention, or any other compound that provides the compounds of this invention upon administration to a patient.
[0048] Pharmaceutically acceptable salts of compounds of formula (I) described in this invention refer to salts derived from inorganic or organic acids and bases. Such acid addition salts include the following: acetates, adipates, alginates, aspartates, benzoates, benzenesulfonates, hydrogen sulfates, butates, citrates, camphorates, cyclopentanepropionates, dodecyl sulfates, ethanesulfonates, fumarates, gluconoses, hemisulfates, hexanoates, hydrochlorides, hydrobromide, hydroiodates, lactates, maleates, methanesulfonates, nicotinates, oxalates, persulfates, picrates, neopentanoates, propionates, succinates, tartrates, toluenesulfonates, and undecanoates. Base addition salts include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts formed with organic bases such as dicyclohexylamine salts, and salts formed with amino acids such as arginine, lysine, etc.
[0049] The compounds of formula (I) described in this invention can also be modified by adding suitable functional groups to improve selective biological characteristics. Such modifications are known in the art and include modifications to improve biopenetration into a given biological system (e.g., blood, lymphatic system, central nervous system), improve oral bioavailability, improve solubility to allow for injection administration, alter metabolism, and change excretion rate.
[0050] In one embodiment, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0051] Pharmaceutically acceptable carriers that can be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffering substances such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and lanolin.
[0052] The pharmaceutical composition can be administered orally, non-gastrointestinally, via inhalation spray, topically, rectally, nasally, buccally, or via an implanted drug reservoir. The term "non-gastrointestinal" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intra-injury, and intracranial injection or infusion techniques. Preferably, the composition can be administered orally, intraperitoneally, or intravenously.
[0053] The amount of the compound that can be combined with a pharmaceutically acceptable carrier to form a single dosage form will depend on the patient being treated and the specific route of administration. Preferably, the composition should be formulated such that the compound can be administered at a dose of 0.01-100 mg / kg body weight / day.
[0054] Example 1
[0055] This embodiment provides Figure 1 The preparation method of 4a in the synthetic route, and the structural formula of 4a are as follows:
[0056]
[0057] The preparation method of compound 4a is as follows:
[0058] 2-Amino-5-methoxythiophenol (2) (5.55 mmol, 0.86 g) and compound 3a (1.85 mmol, 0.5 g) were dissolved in 20 mL of DMSO and heated at 170 °C for 12 hours. After the reaction was complete, the mixture was cooled to room temperature, and 3-5 times (volume) of ice water was added to the reaction solvent. The mixture was extracted three times with dichloromethane. The dichloromethane solution was washed with water and dried on anhydrous Na₂SO₄. The mixture was filtered, and the solvent was evaporated under vacuum. The crude product was analyzed by silica gel column chromatography using a mixture of n-hexane / CH₂Cl₂ (3:1, v / v) as the eluent, yielding a yellowish-brown powder (0.344 g, 40% yield). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.71 (d, J = 7.2, 1.4Hz, 2H), 6.82 (d, 2H), 6.64 (dd, J = 8.9Hz, 2H), 7.71 (d, J = 7.2, 1.4Hz, 2H), 5.80 (m, 4H ),7.53(dd,J=7.5,1.5Hz,2H),7.14(d,J=8.9,2.5,1.0Hz,1H),3.80(d,J=1.5Hz,3H),3.81(dd,J=7.0Hz,2H),2.33(dd,J=7.0,2H); 13C NMR (75MHz, CDCl3) δppm: 169.0, 156.7, 149.6, 146.7, 136.8, 136.1, 134.1, 129.7, 122. 6,122.5,122.4,120.5,114.6,112.7,104.9,78.9,55.8,34.3; EI-MS, m / z: 410.15([M] + ,calcd forC 26 H 22 N2OS, 410.15).
[0059] Example 2
[0060] This embodiment provides Figure 1 The preparation method of 4b in the synthetic route, and the structural formula of 4b are as follows:
[0061]
[0062] The preparation method of compound 4b is as follows:
[0063] 2-Amino-5-methoxythiophenol (2) (5.55 mmol, 0.86 g) and compound 3b (1.85 mmol, 0.5 g) were dissolved in 20 mL of DMSO and heated at 170 °C for 12 hours. After the reaction was complete, the mixture was cooled to room temperature, and 3-5 times (volume) of ice water was added to the reaction solvent. The mixture was extracted three times with dichloromethane. The dichloromethane solution was washed with water and dried on anhydrous Na₂SO₄. The mixture was filtered, and the solvent was evaporated under vacuum. The crude product was analyzed by silica gel column chromatography using a mixture of n-hexane / CH₂Cl₂ (3:1, v / v) as the eluent to obtain a yellowish-brown powder (0.774 g, 90% yield). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.85 (dd, J=8.8, 1.5Hz, 2H), 7.27 (m, J=1.5, 7.8Hz, 2H) ,7.53(dd,J=8.8,2.6Hz,2H),7.35(d,J=7.8Hz,1H),7.24–7.0(m,10H),3.81(s,3H). 13 C NMR (75MHz, CDCl3) δppm: 169.0, 156.7, 146.7, 145.9, 129.7, 129.6, 126.8, 125.7, 123.2, 122.6, 114.6, 55.8; EI-MS, m / z: 408 (calcd. for C 26 H 20 N2OS,408).
[0064] Example 3
[0065] This embodiment provides Figure 1 The preparation method of 4c in the synthetic route, and the structural formula of 4c are as follows:
[0066]
[0067] The preparation method of compound 4c is as follows:
[0068] 2-Amino-5-methoxythiophenol (2) (5.55 mmol, 0.86 g) and compound 3c (1.85 mmol, 0.67 g) were dissolved in 20 mL of DMSO and heated at 170 °C for 12 hours. After the reaction was complete, the mixture was cooled to room temperature, and 3-5 times (volume) of ice water was added to the reaction solvent. The mixture was extracted three times with dichloromethane. The dichloromethane solution was washed with water and dried on anhydrous Na₂SO₄. The mixture was filtered, and the solvent was evaporated under vacuum. The crude product was analyzed by silica gel column chromatography using a mixture of n-hexane / CH₂Cl₂ (3:1, v / v) as the eluent to give a yellowish-brown powder (0.4472 g, yield 52%). 1 H NMR (300MHz, CDCl3) δppm: 3.89 (s, J = 0.40Hz, 3H), 6.96-7.20 (m, 18H), 7.32 (dd, J = 0.40Hz, 2.47Hz, 1H), 7.78 (dd, J = 0.40Hz, 8.24Hz, 2H), 7.91 (dd, J = 0.40 8.92Hz,1H); 13 C NMR (75MHz, CDCl3) δppm: 165.54, 157.85, 148.75, 146.45, 143.41, 141.93, 139.97, 136.30, 132. 13,131.48,127.99,126.99,126.80,123.75,115.81,104.39,56.12; MS (EI), m / z: 495 (calcd.for C 34 H 25 NOS495).
[0069] Example 4
[0070] This embodiment provides Figure 1 The preparation method of 5a in the synthetic route, and the structural formula of 5a are as follows:
[0071]
[0072] The preparation method of compound 5a is as follows:
[0073] A CH₂Cl₂ solution (30 mL) containing 0.5 mmol (0.2 g) of 4a and an anhydrous CH₂Cl₂ solution (4 mL) containing 4 mmol (1.00 g) of BBr₃ were slowly added to an argon atmosphere at -78 °C. The mixture was gradually heated to room temperature and stirred for 20 h. After neutralization with saturated NaHCO₃ solution, it was extracted three times with CH₂Cl₂. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was eluent with CH₂Cl₂ and subjected to silica gel column chromatography to give a white powder (0.1734 g, yield 86.7%). 1H NMR (300MHz, CDCl3) δ (ppm): 7.71 (d, J = 1.5 7.6Hz, 2H), 7.29-5.80 (m, 8H), 7.36 (ds, J = 7.5Hz, 1H), 7.10 (s, J = 1.5Hz, 1H), 6.82 (d, J = 1.57.5Hz 2H), 6.71 (d, J=1.5 7.5Hz, 1H), 6.0 (s, 1H), 3.81 (m, J=7.0Hz, 2H), 2.33 (m, J=7.0Hz, 2H). 13 C NMR (75MHz, CDCl3) δppm: 169.0,155.1,149.6,147.0,137.2,139.6,134.1,129.7,123 .0,122.5,122.4,120.5,114.9,112.7,106.5,78.9,34.3; EI-MS, m / z: 396([M]+,calcd forC 25 H 20 N2OS, 396).
[0074] Example 5
[0075] This embodiment provides Figure 1 The preparation method of 5b in the synthetic route, and the structural formula of 5b are as follows:
[0076]
[0077] The preparation method of compound 5b is as follows:
[0078] A CH₂Cl₂ solution (30 mL) containing 0.5 mmol (0.2 g) of 4b and an anhydrous CH₂Cl₂ solution (4 mL) containing 4 mmol (1.00 g) of BBr₃ were slowly added to an argon atmosphere at -78 °C. The mixture was gradually heated to room temperature and stirred for 20 h. After neutralization with saturated NaHCO₃ solution, it was extracted three times with CH₂Cl₂. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was eluent with CH₂Cl₂ and subjected to silica gel column chromatography to give a white powder (0.1702 g, yield 85.1%). 1H NMR (300MHz, CDCl3) δ (ppm): 7.85 (dd, J=7.2 1.4Hz, 2H), 7.54 -8.18(m,10H),7.27(m,2H),7.36(d,J=8.9Hz,1H),7.1(dd,J=7.2,2.4Hz,1H),6.71(dd,J=8.92.4Hz,1H),6.0(d,1H). 13 C NMR (75MHz, CDCl3) δppm: 169.0,155.1,147.0,145.9,137.2,129.7,129.6,126.8,125 .7,125.4,123.2,123.0,114.9,106.5.EI-MS, m / z: 394 (calcd.forC25H18N2OS,394).
[0079] Example 6
[0080] This embodiment provides Figure 1 The preparation method of 5c in the synthetic route, and the structural formula of 5c are as follows:
[0081]
[0082] Preparation method of compound 5c:
[0083] A solution of CH₂Cl₂ (30 mL) containing 0.5 mmol (0.25 g) of 4 c and a solution of anhydrous CH₂Cl₂ (4 mL) containing 4 mmol (1.00 g) of BBr₃ were slowly added to an argon atmosphere at -78 °C. The mixture was gradually heated to room temperature and stirred for 20 h. After neutralization with saturated NaHCO₃ solution, it was extracted three times with CH₂Cl₂. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was eluent with CH₂Cl₂ and subjected to silica gel column chromatography to give a white powder (0.184 g, 92% yield). 1H NMR (400MHz, DMSO-d6) δppm: 6.96-7.08(m,7H),6.96-7.08(m,7H),7.41(s,1H) ,7.78(d,2H,J=0.40Hz,7.89Hz),7.82(d,1H,J=0.40Hz,8.81Hz),9.92(s,1H); 13 C NMR (100MHz, DMSO-d6) δppm: 163.45, 156.26, 147.60, 146.16, 143.33, 142.03, 140.19, 136.38, 132 .02,131.64,131.16,128.46,127.23,126.67,123.89,116.62,107.23; MS (EI), m / z: 481 (calcd.for C 33 H 23 NOS 481).
[0084] Example 7
[0085] This embodiment provides Figure 1 The preparation method of 6a in the synthetic route, and the structural formula of 6a are as follows:
[0086]
[0087] Preparation method of compound 6a:
[0088] A mixture of 6-methoxybenzothiazol-2-amine (1) (3.7 mmol, 0.67 g), compound 3a (1.85 mmol, 0.5 g), and glacial acetic acid (10 mL) was refluxed in ethanol (20 mL) for 6 h. After removing the solvent, the mixture was purified by recrystallization from ethoxyethanol and dichloromethane (1:1 v / v) to give a pale yellow solid (0.576 g, 86% yield). 1 H NMR (300MHz, CDCl3) δ (ppm): 8.39 (s, J = 7.7, 1H), 7.53 (d, J = 8.6Hz, 2H), 7.29 (dd, J = 8.8 Hz,2H),7.5(dd,J=8.8Hz,2H),7.0(dd,J=8.8Hz,1H),6.78-6.64(m,4H),5.80(td,J=8.6 2.5Hz,4H),3.81(m,2H),3.83(s,3H),2.33(m,2H). 13C NMR (75MHz, CDCl3) δppm: 174.6,160.0,156.7,151.9,141.0,136.1,134.1,128.3,125.9 ,122.6,122.5,122.4,114.6,111.9,104.9,78.9,55.8,34.2; EI-MS, m / z: 437 (calcd.for C27H23N3OS,437).
[0089] Example 8
[0090] This embodiment provides Figure 1 The preparation method of 6b in the synthetic route, and the structural formula of 6b are as follows:
[0091]
[0092] Preparation method of compound 6b:
[0093] A mixture of 6-methoxybenzothiazol-2-amine (1) (3.7 mmol, 0.67 g), compound 3b (1.85 mmol, 0.5 g), and glacial acetic acid (10 mL) was refluxed in ethanol (20 mL) for 6 h. After removing the solvent, the mixture was purified by recrystallization from ethoxyethanol and dichloromethane (1:1 v / v) to give a pale yellow solid (0.609 g, 91% yield). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.45 (d, J = 8.8 Hz, 1H), 7.26 (d, J = 1.6 Hz, 1H), 7.23 (m, J = 5. 1, 2.1Hz, 4H), 7.15–6.97 (m, 9H), 6.90 (dd, J = 8.8, 2.6Hz, 1H), 4.56 (s, 2H), 3.83 (s, 3H). 13 C NMR (75MHz, CDCl3) δppm: 174.6,160.0,156.7,148.2,145.9,141.0 136.1,130.8,129.6,128.3,126.8,125.7,125.1,122.6,114.6,104.9,55.8; EI-MS, m / z: 435 (calcd.for C 27 H 21 N3OS, 435).
[0094] Example 9
[0095] This embodiment provides Figure 1 The preparation method of 6c in the synthetic route, and the structural formula of 6c are as follows:
[0096]
[0097] Preparation method of compound 6c:
[0098] A mixture of 6-methoxybenzothiazol-2-amine (1) (3.7 mmol, 0.67 g), compound 3c (1.85 mmol, 0.67 g), and glacial acetic acid (10 mL) was refluxed in ethanol (20 mL) for 6 h. After removing the solvent, the mixture was purified by recrystallization from ethoxyethanol and dichloromethane (1:1 v / v) to give a pale yellow solid (0.629 g, 94% yield). 1 H NMR (300MHz, CDCl3) δppm: 3.83 (s, 3H, J = 0.40Hz), 7.53-7.0 (m, 18H), 8.39 (s, 1H), 7.75 (d, J = 0.40Hz, 8.24Hz, 2H), 7.31 (m, J = 0.40Hz, 8.92Hz, 2H); 13 C NMR (75MHz, CDCl3) δppm: 174.6, 160.0, 156.7, 142.3, 141.0, 136.1, 135.6, 129. 4,129.1,128.6,127.9,122.6,114.6,104.9,55.8; MS (EI), m / z: 522 (calcd.for C 35 H 26 NOS 522).
[0099] Example 10
[0100] This embodiment provides a formula Figure 1 The preparation method of 7a in the synthetic route, and the structural formula of 7a are as follows:
[0101]
[0102] Preparation method of compound 7a:
[0103] A THF solution (20 mL) containing 6a (1.1 mmol, 0.5 g) and LiAlH4 (3.4 mmol, 0.13 g) were slowly added to an argon atmosphere at 80 °C. The mixture was stirred for 20 h, extracted three times with CH2Cl2, and the resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was purified by recrystallization from diethyl ether and dichloromethane (volume ratio 1:1) to give a white powder (0.47 g, yield 94%). 1H NMR (300MHz, CDCl3) δ (ppm): 8.39 (s, J = 7.7, 1H), 7.53 (d, J = 8.6Hz, 2H), 7.29 (dd, J = 8.8 Hz,2H),7.5(dd,J=8.8Hz,2H),7.0(dd,J=8.8Hz,1H),6.78-6.64(m,4H),5.80(td,J=8.6 2.5Hz,4H),4.49(s,2H),3.96(m,1H),3.83(s,3H),2.33(m,2H). 13 C NMR (75MHz, CDCl3) δppm: 174.4,156.7,147.6,144.5,136.1,134.1,131.8,129.4,127.8,12 2.5,122.4,118.2,112.9,114.7,104.9,79.9,55.8,49.1,34.4; EI-MS, m / z: 439 (calcd.for C 27 H 25 N3OS, 439).
[0104] Example 11
[0105] This embodiment provides Figure 1 The preparation method of 7b in the synthetic route, and the structural formula of 7b are as follows:
[0106]
[0107] Preparation method of compound 7b:
[0108] A THF solution (20 mL) containing 1.1 mmol (0.5 g) of 6b and LiAlH4 (3.4 mmol (0.13 g) were slowly added to an argon atmosphere at 80 °C. The mixture was stirred for 20 h and extracted three times with CH2Cl2. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was purified by recrystallization from diethyl ether and dichloromethane (volume ratio 1:1) to obtain a white powder (0.455 g, yield 91%). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.42 (d, J = 8.8 Hz, 1H), 7.24–7.21 (m, 4H), 7.13–6.98 (m, 10H), 6.90 (m, 2H), 4.54 (s, 2H), 3.96 (s, 1H), 3.82 (s, 3H). 13C NMR (75MHz, CDCl3) δppm: 174.5,156.7,145.9,145.5,143.9,134.3,131.9,129.6, 127.8,126.6,125.9,118.2,114.6,104.7,55.9,49.1; EI-MS, m / z: 437 (calcd.forC 27 H 23 N3OS,437).
[0109] Example 12
[0110] This embodiment provides Figure 1 The preparation method of 7c in the synthetic route, and the structural formula of 7c are as follows:
[0111]
[0112] Preparation method of compound 7c:
[0113] A solution of 20 mL of THF containing 1.1 mmol (0.57 g) of 6c and LiAlH4 (3.4 mmol (0.13 g) was slowly added to argon at 80 °C. The mixture was stirred for 20 h and extracted three times with CH2Cl2. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was purified by recrystallization from diethyl ether and dichloromethane (volume ratio 1:1) to give a white powder (0.475 g, yield 95%). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.20-7.53 (m, 21H), 6.93 (dd, J = 8.8, 1.3Hz, 1H), 4.60 (d, J = 27.6Hz, 2H), 3.97 (s, 1H), 3.81 (d, J = 0.8Hz, 3H). 13 C NMR (75MHz, CDCl3) δppm: 174.5,156.7,145.6,141.3,140.0,139.1,138.0,134.4,131.6, 128.4,128.3,128.0,127.6,118.2,124.7,104.9,55.7,49.3; EI-MS, m / z: 524 (calcd.for C 35 H 28 N2OS,524).
[0114] Example 13
[0115] This embodiment provides Figure 1 The preparation method of 8a in the synthetic route, and the structural formula of 8a are as follows:
[0116]
[0117] Preparation method of compound 8a:
[0118] A CH₂Cl₂ solution (30 mL) containing 7a (1 mmol, 0.44 g) and an anhydrous CH₂Cl₂ solution (4 mL) containing BBr₃ (4 mmol, 1.00 g) were slowly added to an argon atmosphere at -78 °C. The mixture was gradually heated to room temperature and stirred for 20 h. After neutralization with saturated NaHCO₃ solution, it was extracted three times with CH₂Cl₂. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was eluent with CH₂Cl₂ and subjected to silica gel column chromatography to give a white powder (0.19 g, 43% yield). 1 H NMR (300MHz, CDCl3) δ (ppm): 7.25 (m, 3H), 7.1 (m, 3H), 6.71-6.64 (m, 5H), 6.0 (s, 1H), 5.80 (m, J = 8.6 2.5Hz,4H),4.50(s,2H),3.96(s,1H),3.81(m,2H),2.33(m,2H). 13 CNMR (75MHz, CDCl3) δppm: 174.6,155.7,147.6,145.5,136.3,134.1,132.8,129.4,127.6 ,122.5,122.4,117.9,114.9,112.8,106.6,78.9,49.3,34.1; EI-MS, m / z: 425(calcd.forC 26 H 23 N3OS, 425).
[0119] Example 14
[0120] This embodiment provides a formula Figure 1 The preparation method of 9a in the synthetic route, and the structural formula of 9a are as follows:
[0121]
[0122] Preparation method of compound 9a:
[0123] A CH₂Cl₂ solution (30 mL) containing 0.5 mmol (0.22 g) of 6a and an anhydrous CH₂Cl₂ solution (4 mL) containing 4 mmol (1.00 g) of BBr₃ were slowly added to an argon atmosphere at -78 °C. The mixture was gradually heated to room temperature and stirred for 20 h. After neutralization with saturated NaHCO₃ solution, it was extracted three times with CH₂Cl₂. The resulting dichloromethane solution was washed with water and dried over anhydrous sodium sulfate. After filtration, the solvent was evaporated under vacuum. The crude product was eluent with CH₂Cl₂ and subjected to silica gel column chromatography to give a white powder (0.11 g, yield 52%). 1 H NMR (300MHz, CDCl3) δ (ppm): 8.39 (s, J = 7.7, 1H), 7.36-7.29 (m, 3H), 7.50 (dd, J = 8.8Hz, 2H), 7.10 (s ,J=8.8Hz,1H),6.78-6.64(m,5H),6.0(s,1H),5.80(td,J=8.62.5Hz,4H),3.82(m,2H),2.33(m,2H). 13 C NMR (75MHz, CDCl3) δppm: 174.6,160.0,155.9,155.2,141.3,136.4,134.1,128.3,125 .6,123.0,122.5,122.4,114.9,111.9,106.4,78.9,34.1; EI-MS, m / z: 423 (calcd.for C 26 H 21 N3OS,423).
[0124] Example 15: Cytotoxic effect of the compound of the present invention on HT22 cells
[0125] Mouse hippocampal neuron cell line HT22 was routinely cultured in DMEM complete medium containing 10% fetal bovine serum at 37°C in a carbon dioxide incubator containing 5% CO2 and 95% air. Cells in the logarithmic growth phase were harvested, digested with 0.25% trypsin, resuspended in complete medium, counted under a microscope using a cell counting chamber, and the cell concentration was adjusted to 10 × 10⁶ cells / mL. 4Cells were seeded at 100 μL / well in 96-well cell culture plates and cultured overnight to allow cell adhesion. The culture medium was aspirated from the 96-well plates, and the test compound was dissolved in DMSO, diluted with complete culture medium, and added to the 96-well plates at 100 μL / well. After pre-incubation for 24 h, 10 μL of 5 mg / mL MTT was added to each well, and incubated for 2 h. The supernatant was discarded, and 100 μL of DMSO was added to each well. The mixture was shaken to fully dissolve the product, formazan, and the absorbance of each well was measured at 570 nm using a microplate reader. Cell viability was calculated using the formula: (Cell viability promoted by the compound) = 100% * (A test compound - A model group) / (A model group - A blank). The MTT assay results showed that, except for 9a, the other compounds did not exhibit significant cytotoxicity at a concentration of 30 μM. (See attached table for details.) Figure 2 .
[0126] Example 16: The compound of the present invention inhibits L-glutamate-induced cytotoxicity.
[0127] The mouse hippocampal neuron cell line HT22 was cultured in DMEM complete medium containing 10% fetal bovine serum at 37°C under saturated humidity in a carbon dioxide incubator containing 5% CO2 and 95% air. Logarithmically growing cells were harvested, digested with 0.25% trypsin, resuspended in complete medium, counted under a microscope using a cell counting chamber, and adjusted to a concentration of 10 × 10⁴ cells / ml. Cells were then seeded into 96-well cells at 100 μL / well and cultured overnight to allow cell adhesion. The medium was aspirated from the 96-well plates, and the test compound was dissolved in DMSO, diluted with complete medium, and added to the 96-well plates at 100 μL / well. After a 30-minute pre-incubation, 2 μL of 100 mM L-glutamate was added. In the model group, no test compound was added; only 2 μL of 100 mM L-glutamate was added directly. After 24 hours of incubation, 10 μL of 5 mg / mL MTT was added to each well, and incubation was continued for 2 hours. The supernatant was discarded, and 100 μL of DMSO was added to each well. The mixture was shaken to fully dissolve the formazan product. The absorbance of each well was measured using a microplate reader at a wavelength of 570 nm. Cell viability was calculated using the formula: (Compound's cell viability percentage) = 100% * (A test compound - A model group) / (A model group - A blank). The MTT results showed that compounds 4a, 5a, and 8a exhibited significant anti-glutamate-induced cell damage effects at a concentration of 10 μM. (See attached figures). Figure 3 .
[0128] Example 17 – Inhibitory effect of the compounds of the present invention on the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE)
[0129] The colorimetric method reported by Ellman (Ellman, GL; et al. Biochem. Pharmacol. 1961.) assessed the inhibitory activity of AChE / BuChE at 37°C. The test solution consisted of: 0.1 M phosphate buffer (pH 8.0), 0.5 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman's reagent), 0.03 units of AChE / BuChE (Sigma, derived from electric eel), and 0.5 mM acetylthiocholine iodide (or butyrylthiocholine iodide) as the substrate for the enzymatic reaction. The compound to be tested was added to the test solution and pre-incubated with the enzyme at 37°C for 20 minutes, followed by the addition of the substrate. The absorbance change at 412 nm over 5 minutes was measured using a spectrophotometer, and the reaction rates were compared to calculate the percentage of reaction rate inhibition due to the presence of the test compound. Calculate the fractionation rate using at least three copies of the measurements, and calculate the percentage inhibition relative to a control without the compound due to the presence of the test compound. Determine the concentration of the compound that reduces the AChE enzymatic reaction rate by 50% (IC50). 50 The inhibitory concentration is defined as the concentration of a compound that, upon addition, reduces enzyme activity by 50% compared to the state without an inhibitor. The experimental results show that, except for 5a and 6c, all other compounds exhibit good anticholinesterase activity, with stronger inhibitory activity against butyrylcholinesterase. The results are shown in Table 1.
[0130] Table 1. Compounds that inhibit the activity of acetylcholinesterase and butyrylcholinesterase
[0131]
[0132] Example 18 – The compound of the present invention inhibits the self-induced aggregation of Aβ.
[0133] Aβ was monomerized using hexafluoroisopropanol (HFIP) and then lyophilized. (1-42) The test compound was dissolved in DMSO and diluted with 0.215M PBS (pH 8.0). The test solution consisted of 10 μL of Aβ(1-42) solution and 10 μL of the test compound (final concentration 10 μM) or 10 μL of 0.215M PBS (pH 8.0). After incubation at 37℃ for 24 h, 180 μL of 1.5 μM thiamine T solution was added, mixed, and fluorescence intensity was scanned for 300 seconds (λexc = 446 nm; λem = 490 nm). The inhibition rate of the test compound on Aβ self-induced aggregation was calculated using the formula [inhibition rate = 100 - (IFi / IF0 * 100]]. IF0 and IFi are the measured values for the Aβ group and the Aβ + test compound group, respectively. The experimental results show that all compounds inhibited Aβ to varying degrees. (1-42)Aggregation was observed, with compounds 5a and 8a exhibiting stronger inhibitory activity. The results are shown in Table 2.
[0134] Table 2. Th-T fluorescence assay results for the inhibitory effect of compounds on the formation of amyloid fibrils Aβ.
[0135]
[0136] Example 19 – Interactions between compounds 5a and 8a of the present invention and copper ions
[0137] The interactions between compounds 5a and 8a and copper ions were investigated using a UV-Vis spectrophotometer. Experimental procedure: The mother liquor of the test compounds was diluted with methanol and placed in a 1 cm cuvette for UV-Vis absorption spectroscopy. Then, copper ions and compounds were added to the cuvette solution in a 1:1 ratio, and after appropriate stirring, the UV-Vis absorption spectra of the copper ion / compound ratio were measured. Results are shown below. Figure 4 .
[0138] Figure 4 Figure A (compound 5a) Figure 4 In Figure B (compound 8a), the UV absorption curve shifted after the addition of copper ions. This shift indicates that the compound can chelate with copper ions, suggesting that compounds 5a and 8a have a certain copper ion chelating effect.
[0139] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. The application of benzothiazole-carbazole heterocombinants in the preparation of anti-AD drugs, characterized in that, The benzothiazole-carbazole hybrid compound is selected from one or more of 4a, 4b, 4c, 5a, 5b, 5c, 6a, 6b, 6c, 7a, 7b, 7c, 8a, and 9a; 4a: ;4b: ; 4c: 5a: ; 5b: 5c: ; 6a: ;6b: ; 6c: 7a: ; 7b: 7c: ; 8a: 9a: 。 2. The use of the benzothiazole-carbazole heterocomplex according to claim 1 in the preparation of anti-AD drugs, characterized in that, The compound possesses antioxidant properties, copper ion chelation effects, inhibition of Aβ aggregation, and inhibition of cholinesterase activity.
Citation Information
Patent Citations
Benzothiazole derivative and application thereof
CN102558091A
Benzothiazole derivative containing triphenylethylene or tetraphenylethylene structure and having aggregation-induced emission property and preparation method and application thereof
CN103804318A
Ferroelectric fluorescent self-assembly compound and organic electronic element including the same
US20220009908A1
